Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vanguard Total International Bond Index Fund ETF (BNDX) vs Eli Lilly And Co (LLY) Price & Performance

Vanguard Total International Bond Index Fund ETFTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Vanguard Total International Bond Index Fund ETF vs Eli Lilly And Co — how do they compare? Vanguard Total International Bond Index Fund ETF trades at $48.01, while Eli Lilly And Co trades at $1,148.14 (market cap $1.03T). The key difference: Eli Lilly And Co pays a 0.6% dividend while Vanguard Total International Bond Index Fund ETF pays none. Which is the better fit depends on your goals.

BNDXLLY
52-Week High
$49.91$1.24K
52-Week Low
$47.57$625.65
Market Cap
$1.03T
Sector
Health
Enterprise Value
$1.07T
Dividend Yield
0.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vanguard Total International Bond Index Fund ETF

BNDX trades at $47.89, down 0.4% with a bearish technical signal from moving averages. The ETF shows neutral momentum oscillators but faces pressure from rising bond yields and Fed uncertainty. Recent news highlights strong bond ETF inflows as investors seek yield amid market volatility, though inflation concerns persist.

Outlook remains cautious due to potential Fed rate hikes and macroeconomic headwinds. The fund offers steady income through dividends but faces valuation pressure from rising rates. Key risks include interest rate sensitivity and global economic shifts impacting international bond performance.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,185.08, down slightly (-0.29%) on the day, with a strong bullish technical signal from moving averages. The company demonstrates exceptional fundamental strength, with revenue surging to $65.18B in 2025 and a net income margin of 34.99%. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive, with a consensus price target of $1,360.

The outlook for LLY remains robust, driven by its dominant position in the high-growth weight loss and Alzheimer's drug markets. Key opportunities include continued revenue expansion and pipeline advancements. Primary risks involve intensifying competition, particularly from Novo Nordisk's obesity pill, and the stock's premium valuation multiples, which demand sustained high growth to justify.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Vanguard Total International Bond Index Fund ETF

The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.

Read more on BNDX

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY